J Korean Soc Transplant.  2013 Jun;27(2):37-41.

The Management of HCV Recurrence after Liver Transplantation

Affiliations
  • 1Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. kwleegs@gmail.com

Abstract

Liver transplantation (LT) for hepatitis C virus (HCV)-related liver diseases has been increasing in Korea. HCV recurrence, a serious complication after LT, can accelerate liver cirrhosis and fatal graft loss. Therefore, the prevention and appropriate treatment for HCV recurrence can improve a LT patient's quality of life and survival. In considering the relationship between immunosuppressants and HCV recurrence, there is no clear difference in HCV recurrence between the immunosuppressant tacrolimus or cyclosporine, and the use of steroids for patients with HCV is still under debate. In the management of HCV recurrence, direct-acting antivirals, such as protease inhibitors, polymerase inhibitors, or other nonstructural protein inhibitors will open a new era in HCV treatment. However, their safety and drug interactions with immunosuppressants should be evaluated for patients after LT.

Keyword

HCV; Immunosuppression; Liver transplantation

MeSH Terms

Antiviral Agents
Cyclosporine
Drug Interactions
Hepacivirus
Humans
Immunosuppression
Immunosuppressive Agents
Korea
Liver
Liver Cirrhosis
Liver Diseases
Liver Transplantation
Protease Inhibitors
Quality of Life
Recurrence
Steroids
Tacrolimus
Transplants
Antiviral Agents
Cyclosporine
Immunosuppressive Agents
Protease Inhibitors
Steroids
Tacrolimus
Full Text Links
  • JKSTN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error